WO2007146171A3 - Purified high molecular weight adiponectin and uses thereof - Google Patents

Purified high molecular weight adiponectin and uses thereof Download PDF

Info

Publication number
WO2007146171A3
WO2007146171A3 PCT/US2007/013584 US2007013584W WO2007146171A3 WO 2007146171 A3 WO2007146171 A3 WO 2007146171A3 US 2007013584 W US2007013584 W US 2007013584W WO 2007146171 A3 WO2007146171 A3 WO 2007146171A3
Authority
WO
WIPO (PCT)
Prior art keywords
adiponectin
hmw
molecular weight
high molecular
complex
Prior art date
Application number
PCT/US2007/013584
Other languages
French (fr)
Other versions
WO2007146171A2 (en
Inventor
David H Lee
Cory Rillahan
Shinji Suzuki
Original Assignee
Tufts College
David H Lee
Cory Rillahan
Shinji Suzuki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College, David H Lee, Cory Rillahan, Shinji Suzuki filed Critical Tufts College
Publication of WO2007146171A2 publication Critical patent/WO2007146171A2/en
Publication of WO2007146171A3 publication Critical patent/WO2007146171A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to high molecular weight (HMW) adiponectin, methods for its purification, and uses of the HMW adiponectin. Embodiments of the inventions includes an isolated and purified adiponectin complex composed of 18 adiponectin monomers substantially free of adiponectin trimers and hexamers; an article of manufacture comprising the HMW adiponectin complex and instructions for use of the complex in a mammalian patient; a method of preparing a purified HMW adiponectin; a method of predicting the risk of developing Type 2 diabetes by analyzing the HMW adiponectin content in a blood plasma; and a method of determining the effectiveness of a Type 2 diabetes treatment.
PCT/US2007/013584 2006-06-08 2007-06-08 Purified high molecular weight adiponectin and uses thereof WO2007146171A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81200806P 2006-06-08 2006-06-08
US60/812,008 2006-06-08
US89854307P 2007-01-31 2007-01-31
US60/898,543 2007-01-31

Publications (2)

Publication Number Publication Date
WO2007146171A2 WO2007146171A2 (en) 2007-12-21
WO2007146171A3 true WO2007146171A3 (en) 2008-02-14

Family

ID=38657074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013584 WO2007146171A2 (en) 2006-06-08 2007-06-08 Purified high molecular weight adiponectin and uses thereof

Country Status (1)

Country Link
WO (1) WO2007146171A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20086024A0 (en) * 2008-10-29 2008-10-29 Oulun Yliopisto New pharmaceutical product
EP2820034A4 (en) * 2012-02-29 2015-07-15 Ambrx Inc Modified adiponectin polypeptides and their uses
CN104673755A (en) * 2014-11-06 2015-06-03 中国医学科学院北京协和医院 Anti-human macromolecule adiponectin monoclonal antibody and application thereof
WO2020201195A2 (en) * 2019-04-04 2020-10-08 Bayer Aktiengesellschaft Agonists of adiponectin
CN113671196B (en) * 2021-07-29 2023-09-12 中国人民解放军空军军医大学 Method for studying influence of interaction of LAIR-1 molecules and adiponectin on T cell activation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
PAJVANI U B ET AL: "Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 11, 14 March 2003 (2003-03-14), pages 9073 - 9085, XP002251775, ISSN: 0021-9258 *
SUZUKI ET AL: "The oligomeric structure of high molecular weight adiponectin", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 5, 24 February 2007 (2007-02-24), pages 809 - 814, XP005916830, ISSN: 0014-5793 *
WAKI H ET AL: "Impaired Multimerization of Human Adiponectin Mutants Associated with Diabetes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 41, 10 October 2003 (2003-10-10), pages 40352 - 40363, XP002988190, ISSN: 0021-9258 *
WANG YU ET AL: "Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 24, 18 April 2006 (2006-04-18), pages 16391 - 16400, XP002458709, ISSN: 0021-9258 *
XU AIMIN ET AL: "Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 18, May 2005 (2005-05-01), pages 18073 - 18080, XP002458790, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2007146171A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
Biot et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities
NO20064388L (en) Casein-derived peptides and therapeutic uses thereof
WO2007146171A3 (en) Purified high molecular weight adiponectin and uses thereof
DK1755634T3 (en) Oligopeptides to decrease elevated blood urea concentration
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2006086586A3 (en) Anti-interferon alpha monoclonal antibodies and methods for use
MX2008007716A (en) Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood.
MY153198A (en) Inhibitors of protein aggregation
WO2007068985A3 (en) Diagnosis and prognosis of colorectal cancer
UA116871C2 (en) METHOD OF TREATMENT OF MYELODYLASPLASTIC SYNDROME, THALASEMIA AND SERIOUS-CELL ANEMIA WITH THE USE OF ACTIVIPURIA ANTAGONISTU ANTAGONIST
WO2009048072A1 (en) ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
EA201490749A1 (en) ONE-NUCLEOTIC POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL REACTION TO GLETYRAMER ACETATE
EA201390543A1 (en) CYTOKINE BIOMARKERS AS BIOMARKERS PREDICTING A CLINICAL RESPONSE TO GLETIRAMER ACETATE
WO2008021976A3 (en) Anti-interferon alpha monoclonal antibodies and methods for use
EA201001749A1 (en) METHOD OF TREATMENT OF DIFFERENTIATED ARTHRITIS
PL2057467T3 (en) Method for diagnosis of a disease involving an anti-at1-receptor antibody
Schmid et al. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function
UA91137C2 (en) Peptide capable of enhancing capillaries resistance, pharmaceutical composition based thereon and method of use thereof
WO2007143161A3 (en) Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2006044107A3 (en) Method of treating human preeclampsia employing resibufagenin
WO2007015094A3 (en) Use of peptides for imaging blood clots

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809418

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07809418

Country of ref document: EP

Kind code of ref document: A2